Literature DB >> 4812408

Benorylate in management of Still's disease.

R H Powell, B M Ansell.   

Abstract

The present recommended dose of benorylate is not satisfactory for the management of children suffering from inflammatory polyarthritis. A starting dose of 200 mg/kg/day should be used, and the salicylate level checked at seven days and the dosage adjusted to give an anti-inflammatory effect-that is, a blood salicylate level of between 25 and 30 mg/100 ml. Once a satisfactory level has been achieved, this dosage should be maintained with occasional monitoring of the salicylate level. The paracetamol level does not need to be estimated as it tends to follow the salicylate level, provided that liver function is normal; thus it is quite safe to monitor only the salicylate level. Given in an adequate dosage, benorylate seems to be an acceptable salicylate preparation for use in juveniles suffering from chronic polyarthritis.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4812408      PMCID: PMC1632990          DOI: 10.1136/bmj.1.5899.145

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  8 in total

1.  Rapid determination of salicylate in biological fluids.

Authors:  P TRINDER
Journal:  Biochem J       Date:  1954-06       Impact factor: 3.857

2.  Gastric bleeding and benorylate, a new aspirin.

Authors:  D N Croft; J H Cuddigan; C Sweetland
Journal:  Br Med J       Date:  1972-09-02

3.  Comparison of aspirin and benorylate in the treatment of rheumatoid arthritis.

Authors:  D L Beales; H C Burry; R Grahame
Journal:  Br Med J       Date:  1972-05-27

4.  Biopsy diagnosis of amyloidosis in rheumatoid arthritis. Malabsorption caused by intestinal amyloid deposits.

Authors:  T Pettersson; O Wegelius
Journal:  Gastroenterology       Date:  1972-01       Impact factor: 22.682

5.  The management of juvenile chronic polyarthritis (Still's disease).

Authors:  B M Ansell
Journal:  Practitioner       Date:  1972-01

6.  Absorption kinetics of aspirin in man following oral administration of an aqueous solution.

Authors:  M Rowland; S Riegelman; P A Harris; S D Sholkoff
Journal:  J Pharm Sci       Date:  1972-03       Impact factor: 3.534

7.  Malabsorption in rheumatoid disease.

Authors:  N H Dyer; M J Kendall; C F Hawkins
Journal:  Ann Rheum Dis       Date:  1971-11       Impact factor: 19.103

8.  Benorylate and indomethacin in the treatment of rheumatoid disease: a double-blind clinical trial.

Authors:  M Franke; G Manz
Journal:  Curr Ther Res Clin Exp       Date:  1972-03
  8 in total
  2 in total

1.  Oral antipyretic therapy: evaluation of benorylate, an ester of acetylsalicylic acid and paracetamol.

Authors:  S Similä; S Keinänen; K Kouvalainen
Journal:  Eur J Pediatr       Date:  1975-12-09       Impact factor: 3.183

Review 2.  Non-steroidal anti-inflammatory drugs. Current status and rational therapeutic use.

Authors:  F D Hart; E C Huskisson
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.